Heparin-Functionalized Adsorbents Eliminate Central Effectors of Immunothrombosis, including Platelet Factor 4,

Marie Ebeyer-Masotta1, Tanja Eichhorn1, René Weiss1

  • 1Center for Biomedical Technology, Department for Biomedical Research, Danube University Krems, 3500 Krems, Austria.

Insights

Heparin-functionalized adsorbents can remove key drivers of inflammation and thrombosis, such as activated platelets and neutrophil extracellular traps (NETs). This approach may help treat thrombotic complications in sepsis and COVID-19.

Area of Science:

  • Biomedical Engineering
  • Immunology
  • Hematology

Background:

  • Inflammation and thrombosis are linked in critical illnesses like sepsis and COVID-19.
  • Thrombotic complications indicate severe disease, leading to organ failure and death.
  • Immunothrombosis involves the complement/tissue factor/neutrophil axis, activated platelets, and neutrophil extracellular traps (NETs).

Purpose of the Study:

  • To investigate the potential of heparin-functionalized adsorbents in mitigating immunothrombosis.
  • To evaluate the capacity of these adsorbents to deplete key effectors of immunothrombosis.

Main Methods:

  • Utilized adsorbents functionalized with endpoint-attached heparin.
  • Assessed the depletion of activated platelets, platelet-derived extracellular vesicles (pEVs), platelet factor 4 (PF4), high-mobility box 1 protein (HMGB1), histones, and nucleosomes.

Main Results:

  • Heparin-functionalized adsorbents efficiently depleted activated platelets, pEVs, PF4, HMGB1, histones, and nucleosomes.
  • These depleted factors are central effectors of deregulated immunothrombosis.

Conclusions:

  • Heparin-functionalized adsorbents can eliminate key drivers of immunothrombosis.
  • This depletion mechanism, rather than direct pathogen binding, may be clinically relevant for managing thrombosis in sepsis and COVID-19.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
975
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
682
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
43
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K